Tammy Hughes
Family · Sevierville, TNNPI 1225483373
Payments from drug & device makers
Across 92 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$367
- GSK$259
- Novo Nordisk$161
- Astellas Pharma US Inc$125
- Pfizer$101
- Amgen$67
- plus $467 from 15 others
What the payments were for
- Food & beverage$1,542100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 22 | $367 |
| GSK | 17 | $259 |
| Novo Nordisk | 9 | $161 |
| Astellas Pharma US Inc | 5 | $125 |
| Pfizer | 5 | $101 |
| Amgen | 5 | $67 |
| Lilly USA, LLC | 4 | $63 |
| Boehringer Ingelheim | 4 | $62 |
| Bayer | 3 | $44 |
| Biohaven Pharmaceuticals, Inc. | 3 | $40 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Dexcom, Inc. | 1 | $29 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| AbbVie | 2 | $27 |
| Merck | 2 | $27 |
| Novartis | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Radius Health, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| AstraZeneca | 1 | $14 |
How this compares
$1,548 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $118,654 |
| JardianceEmpagliflozin | 56 | $71,309 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $40,749 |
| EliquisApixaban | 25 | $26,995 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $13,972 |
| VascepaIcosapent Ethyl | 14 | $13,336 |
| JanuviaSitagliptin Phosphate | 12 | $11,152 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $10,917 |
| Omeprazole | 199 | $3,142 |
| Atorvastatin Calcium | 394 | $2,768 |
| Losartan Potassium | 336 | $2,766 |
| Gabapentin | 254 | $2,608 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 119 | $2,501 |
| Famotidine | 113 | $2,292 |
| Levothyroxine Sodium | 279 | $1,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $161 | $118,65483 claims |
| Boehringer IngelheimJardiance | $62 | $71,30956 claims |
| PfizerEliquis | $101 | $26,99525 claims |
| AstraZenecaSymbicort | $14 | $13,97226 claims |
| MerckJanuvia | $27 | $11,15212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.
Other family in Sevierville
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.